Background: Despite advances in medical and surgical management of ovarian cancer, recurrence is still significant issue with secondary cytoreductive surgery (SCS) being considered as treatment option for carefully selected patients. Objective: To assess short term and follow up outcomes of secondary cytoreductive surgery among recurrent ovarian cancer patients. Patients and Method: After approval of ethics committee, this study included forty four female patients who were diagnosed with recurrent ovarian cancer between 2014 and 2019. They were treated at Surgery Department, Kuwait Cancer Control Center, Kuwait and both Surgery and Gynecology Departments, Suez Canal University Hospitals, Ismailia, Egypt. All patients had undergone secondary cytoreductive surgery and were followed up for 4-40 months. Results: The most common site of recurrence at presentation was local pelvic recurrence (52.27%) with peritoneal disease reported among 34.09%. Ascites was found among 18.18% of patients. The most commonly reported complications included ileus (13.64%), DVT (9.09) and wound infection (9.09%). Local recurrence after SCS was reported among 34.09% of patients. Mean disease free survival (DFS) was 24.8 months. Conclusion: secondary cytoreductive surgery for recurrent ovarian cancer is feasible when patient selection is appropriate and it can offer the patient with a better outcome regarding the DFS.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
